// Company Overview //
| Stock Name | 華康生物醫學控股有限公司 |
|---|
| Stock Code | 08622 |
|---|
| Company Full Name | 華康生物醫學控股有限公司 |
|---|
| Industry | 醫療保健 |
|---|
| Principal Activities | 公司主要於中國從事研發、生產、營銷及銷售體外診斷試劑及輔助生育用品和設備。 |
|---|
| Listing Date | 2018-12-13 |
|---|
| Listing Rules Era | Old Rules |
|---|
| Listing Rules Chapter | No data |
|---|
| Weighted Voting Rights (WVR) | No |
|---|
| Registered Address (Mainland China) | 香港九龍科學館道16號么地道77號華懋廣場10樓1004室 |
|---|
| Business Address (Hong Kong) | No data |
|---|
| Place of Incorporation | 開曼群島 |
|---|
| Listing Method | 發售以供認購 + 發售以供配售 |
|---|
| Listing Board | GEM |
|---|
| Website | https://joyzymebiotech.com/ |
|---|
| Share Registrar | 卓佳證券登記有限公司 |
|---|
| Registrar Contact | (852)2980 1333 |
|---|
| A-Share/US Dual Listing | No data |
|---|
// Offering Information //
| Offer Price | HK$ 0.50 / shares |
|---|
| Total Funds Raised | HK$ 50,000,000 |
|---|
| Subscription Multiple | 131.5x |
|---|
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|
| Market Cap at Listing (HKEX) | HK$ 200,000,000 |
|---|
// First Day Performance
| First Day Close | Loading... |
|---|
| First Day Open | HK$ 0.495 |
|---|
| First Day Change | -6.00% |
|---|
| First Day Volume | 125728000.0 |
|---|
| First Day Turnover | 64066800.0 |
|---|
// Price Chart //
// Use of Proceeds
| Use of Proceeds | 1、所得款項凈額41.5%（或6.9百萬港元）將用于開發新產品、改良我們的現有產品及開展國際合作項目；
2、所得款項凈額27.3%（或4.5百萬港元）將用于擴展我們的銷售網絡以及加強我們的銷售及營銷活動；
3、所得款項凈額27.9%（或4.6百萬港元）將用于發展輔助生育用品業務；
4、所得款項凈額3.3%（或548,000港元）將用于為營運資金撥付資金。 |
|---|
// Underwriting Syndicate //
联席账簿管理人 (2)
利得证券(香港)有限公司
长雄证券有限公司
联席牵头经办人 (3)
利得证券(香港)有限公司
力高证券有限公司
勤丰证券有限公司
// Cornerstone Investors //
This stock has no cornerstone investors.
// Directors & Management //
| Chairman | 張玉靜 |
|---|
| Company Secretary | 周麗麒 |
|---|
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 張曙光(34.88%);張賢陽(23.02%) |
|---|
Disclaimer & Risk Warning
Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.
